JP2019518003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518003A5 JP2019518003A5 JP2018555141A JP2018555141A JP2019518003A5 JP 2019518003 A5 JP2019518003 A5 JP 2019518003A5 JP 2018555141 A JP2018555141 A JP 2018555141A JP 2018555141 A JP2018555141 A JP 2018555141A JP 2019518003 A5 JP2019518003 A5 JP 2019518003A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peptide
- vectors
- vector
- interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022124716A JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326082P | 2016-04-22 | 2016-04-22 | |
| US62/326,082 | 2016-04-22 | ||
| PCT/US2017/028755 WO2017184933A1 (en) | 2016-04-22 | 2017-04-21 | Methods and compositions to enhance the anti-inflammatory effects of interleukin 10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124716A Division JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518003A JP2019518003A (ja) | 2019-06-27 |
| JP2019518003A5 true JP2019518003A5 (enExample) | 2020-05-14 |
| JP7163189B2 JP7163189B2 (ja) | 2022-10-31 |
Family
ID=60116475
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555141A Active JP7163189B2 (ja) | 2016-04-22 | 2017-04-21 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
| JP2022124716A Pending JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022124716A Pending JP2022169585A (ja) | 2016-04-22 | 2022-08-04 | インターロイキン１０の抗炎症効果を亢進するための方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20190112354A1 (enExample) |
| EP (1) | EP3445849B1 (enExample) |
| JP (2) | JP7163189B2 (enExample) |
| KR (1) | KR102430455B1 (enExample) |
| CN (1) | CN109477085B (enExample) |
| AU (1) | AU2017252327B2 (enExample) |
| CA (1) | CA3019846A1 (enExample) |
| DK (1) | DK3445849T3 (enExample) |
| IL (1) | IL262195B2 (enExample) |
| RU (1) | RU2731160C2 (enExample) |
| WO (1) | WO2017184933A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3021873T1 (sl) | 2013-07-18 | 2018-12-31 | Xalud Therapeutics, Inc. | Sestavek za zdravljenje vnetne sklepne bolezni |
| CA3087238A1 (en) | 2018-05-24 | 2019-11-28 | Celanese EVA Performance Polymers Corporation | Implantable device for sustained release of a macromolecular drug compound |
| EP3803866A4 (en) | 2018-05-24 | 2022-03-16 | Nureva Inc. | METHOD, APPARATUS, AND COMPUTER READABLE MATERIALS FOR MANAGING SEMI-CONSTANT (PERSISTENT) SOUND SOURCES IN MICROPHONE CATCH/HOME AREAS |
| CN111989068B (zh) | 2018-05-24 | 2024-10-25 | 塞拉尼斯伊娃高性能聚合物公司 | 用于持续释放大分子药物化合物的可植入器件 |
| CN112779285B (zh) * | 2019-11-11 | 2023-01-06 | 百奥赛图(北京)医药科技股份有限公司 | 人源化il-10和il-10ra基因改造动物的构建方法和应用 |
| EP4329734A4 (en) | 2021-04-26 | 2025-04-02 | Celanese EVA Performance Polymers LLC | Implantable device for the delayed release of a macromolecular drug compound |
| KR102466921B1 (ko) * | 2021-06-29 | 2022-11-14 | 주식회사 오에이티씨 | 인터루킨-4를 암호화하는 유전자를 포함하는 신경병증성 통증의 예방 또는 치료용 약학적 조성물 |
| WO2023114958A1 (en) * | 2021-12-16 | 2023-06-22 | Xalud Therapeutics, Inc. | Dosing regimen for il-10 encoding expression construct |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5716804A (en) * | 1995-04-19 | 1998-02-10 | Schering Corporation | Mammalian interleukin-10 (IL-10) super-activating receptors; and variants |
| US7261882B2 (en) * | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| DE602006011311D1 (de) * | 2005-05-31 | 2010-02-04 | Univ Colorado | Il-10 mutante |
| EP2550359B1 (en) * | 2010-03-23 | 2017-08-09 | Intrexon Corporation | Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof |
| US9315825B2 (en) * | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| WO2013103966A1 (en) * | 2012-01-06 | 2013-07-11 | The Regents Of The University Of Colorado, A Body Corporate | Methods for the treatment of multiple sclerosis and other demyelinating disorders |
| SI3021873T1 (sl) * | 2013-07-18 | 2018-12-31 | Xalud Therapeutics, Inc. | Sestavek za zdravljenje vnetne sklepne bolezni |
-
2017
- 2017-04-21 RU RU2018140988A patent/RU2731160C2/ru active
- 2017-04-21 CN CN201780025135.5A patent/CN109477085B/zh active Active
- 2017-04-21 KR KR1020187033641A patent/KR102430455B1/ko active Active
- 2017-04-21 AU AU2017252327A patent/AU2017252327B2/en active Active
- 2017-04-21 CA CA3019846A patent/CA3019846A1/en active Pending
- 2017-04-21 DK DK17786683.7T patent/DK3445849T3/da active
- 2017-04-21 US US16/094,006 patent/US20190112354A1/en not_active Abandoned
- 2017-04-21 IL IL262195A patent/IL262195B2/en unknown
- 2017-04-21 WO PCT/US2017/028755 patent/WO2017184933A1/en not_active Ceased
- 2017-04-21 EP EP17786683.7A patent/EP3445849B1/en active Active
- 2017-04-21 JP JP2018555141A patent/JP7163189B2/ja active Active
-
2022
- 2022-08-04 JP JP2022124716A patent/JP2022169585A/ja active Pending
-
2024
- 2024-04-29 US US18/648,678 patent/US20240352089A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2018140988A (ru) | Способы и композиции для усиления противовоспалительных эффектов интерлейкина 10 | |
| JP7731579B2 (ja) | 細胞並びにその使用方法及び製造方法 | |
| Ireland et al. | Seeking balance: Potentiation and inhibition of multiple sclerosis autoimmune responses by IL-6 and IL-10 | |
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| Li et al. | Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis | |
| JP2019524721A5 (enExample) | ||
| JP5980508B2 (ja) | 自己免疫障害に対する処置方法 | |
| US20220073585A1 (en) | Chimeric antigen receptor memory-like (carml) nk cells and methods of making and using same | |
| ES2908553T3 (es) | Métodos para expandir una población de macrófagos alveolares en un cultivo de larga duración | |
| RU2014132426A (ru) | Частичные конструкты мнс и способы их применения | |
| CN115135330A (zh) | 修饰的干细胞及其使用方法 | |
| WO2022012531A1 (zh) | 一种经修饰的免疫细胞的制备方法 | |
| JP2014523252A5 (enExample) | ||
| WO2022187280A1 (en) | Personalized redirection and reprogramming of t cells for precise targeting of tumors | |
| Mondanelli et al. | Islet antigen-pulsed dendritic cells expressing ectopic IL-35Ig protect nonobese diabetic mice from autoimmune diabetes | |
| WO2024059821A2 (en) | Car t cell compositions for treatment of cancer | |
| JP7766674B2 (ja) | 二重ｃａｒ－ｔ細胞 | |
| ES2972793T3 (es) | Células diseñadas para inducir tolerancia | |
| AU2023209589A1 (en) | Modulation of suv39h1 expression by rnas | |
| US20090060889A1 (en) | Ii-RNAi involved Ii suppression in cancer immunotherapy | |
| WO2025101276A1 (en) | Compositions and methods for making and using immune cells | |
| Yang et al. | Downregulating immunogenicity of Schwann cells via inhibiting a potential target of class II transactivator (CIITA) gene | |
| Horn et al. | Gene therapy in the transplantation of allogeneic organs and stem cells | |
| WO2015169994A1 (es) | Composición capaz de modular la actividad de sidt1 para el tratamiento de enfermedades infecciosas inflamatorias o autoinmunes mediadas por ifn | |
| Zhang | Leading to Immune Tolerogenic DCs for Preventing Alloimmune Rejection |